Monotypic IgG1-kappa Atypical Anti-Glomerular Basement Membrane Nephritis: A Case Report
Autor: | Danielle Lee, Viresh Mohanlal, Harold Watson, Steven Carlan, Mario Madruga, Maxim Olivier |
---|---|
Rok vydání: | 2019 |
Předmět: |
Renal failure
medicine.medical_specialty Cyclophosphamide medicine.medical_treatment 030232 urology & nephrology Case Report 030204 cardiovascular system & hematology lcsh:RC870-923 urologic and male genital diseases Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Atypical anti-glomerular basement membrane Medicine Nephritis medicine.diagnostic_test business.industry Glomerular basement membrane Mycophenolate mofetil Glomerulonephritis lcsh:Diseases of the genitourinary system. Urology medicine.disease medicine.anatomical_structure Nephrology Plasmapheresis Renal biopsy business medicine.drug Rare disease Hemorrhagic cystitis |
Zdroj: | Case Reports in Nephrology and Dialysis, Vol 9, Iss 1, Pp 8-14 (2019) Case Reports in Nephrology and Dialysis |
ISSN: | 2296-9705 |
DOI: | 10.1159/000498844 |
Popis: | Anti-glomerular basement membrane (anti-GBM) glomerulonephritis is a rare disease caused by autoantibodies against the glomerular basement membrane. Atypical anti-GBM nephritis is clinically less aggressive and characterized by the absence of circulating autoantibodies to the basement membrane. A previously healthy 53-year-old white woman presented with a rising creatinine over a short observation period. Renal biopsy, urinary sediment, and laboratory testing confirmed the diagnosis of atypical anti-GBM disease. She received plasmapheresis, steroids, and cyclophosphamide. She developed hemorrhagic cystitis early in the treatment from oral cyclophosphamide and mycophenolate mofetil was substituted as a first-line drug. She responded favorably and continued on mycophenolate mofetil without evidence of relapse. Despite the absence of circulating autoantibodies, a diagnosis of atypical anti-GBM nephritis should not be excluded if a high index of clinical suspicion exists. Early renal biopsy should be considered. Mycophenolate mofetil may be a reasonable replacement for oral cyclophosphamide in the treatment of atypical anti-GBM disease when cyclophosphamide is contraindicated. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |